MCID: LYM002
MIFTS: 29

Lymphoplasmacyte-Rich Meningioma

Categories: Cancer diseases, Immune diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoplasmacyte-Rich Meningioma

MalaCards integrated aliases for Lymphoplasmacyte-Rich Meningioma:

Name: Lymphoplasmacyte-Rich Meningioma 11 14 16 71
Lymphoplasmocyte-Rich Meningioma 11
Meningioma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:4591
NCIt 49 C4720
SNOMED-CT 68 19453003
UMLS 71 C0025286 C0431119

Summaries for Lymphoplasmacyte-Rich Meningioma

MalaCards based summary: Lymphoplasmacyte-Rich Meningioma, also known as lymphoplasmocyte-rich meningioma, is related to meningioma, familial and rapidly involuting congenital hemangioma. An important gene associated with Lymphoplasmacyte-Rich Meningioma is MIB1 (MIB E3 Ubiquitin Protein Ligase 1), and among its related pathways/superpathways is Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Thrombin and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotype is no phenotypic analysis.

Related Diseases for Lymphoplasmacyte-Rich Meningioma

Graphical network of the top 20 diseases related to Lymphoplasmacyte-Rich Meningioma:



Diseases related to Lymphoplasmacyte-Rich Meningioma

Symptoms & Phenotypes for Lymphoplasmacyte-Rich Meningioma

MGI Mouse Phenotypes related to Lymphoplasmacyte-Rich Meningioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 8.92 CD68 CLDN6 MIB1 OLIG2

Drugs & Therapeutics for Lymphoplasmacyte-Rich Meningioma

Drugs for Lymphoplasmacyte-Rich Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic acid Approved Phase 4 1197-18-8 5526
3
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Prilocaine Approved Phase 4 721-50-6 4906
6 Fibrin Tissue Adhesive Phase 4
7 Antifibrinolytic Agents Phase 4
8 Hemostatics Phase 4
9 Coagulants Phase 4
10 Anesthetics, Local Phase 4
11 Anesthetics Phase 4
12 Vasoconstrictor Agents Phase 4
13 Epinephryl borate Phase 4
14 Bronchodilator Agents Phase 4
15 Neurotransmitter Agents Phase 4
16 Adrenergic beta-Agonists Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Adrenergic Agonists Phase 4
19 Adrenergic Agents Phase 4
20 Anti-Asthmatic Agents Phase 4
21 Respiratory System Agents Phase 4
22 Mydriatics Phase 4
23 Sympathomimetics Phase 4
24
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
25
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
26
Cisatracurium Approved, Investigational Phase 3 96946-41-7 62887
27
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
28
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Aminolevulinic acid Approved Phase 3 106-60-5 137
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Antihypertensive Agents Phase 3
40 Photosensitizing Agents Phase 3
41 Dermatologic Agents Phase 3
42
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
43
Aldesleukin Approved Phase 2 110942-02-4
44
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Hydroxyurea Approved Phase 2 127-07-1 3657
47
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Verapamil Approved Phase 2 152-11-4, 52-53-9 2520
50
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
13 A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas Recruiting NCT05130866 Phase 2, Phase 3 REC-2282;Placebo
14 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
15 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Unknown status NCT03016091 Phase 2 Pembrolizumab
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
18 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
19 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
20 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
21 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
22 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
23 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
24 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
25 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
28 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
29 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
30 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
31 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
32 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
35 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
36 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
37 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
38 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
39 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
40 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
41 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
42 Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations Recruiting NCT02523014 Phase 2 Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib
43 SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Recruiting NCT04298541 Phase 2 Ga-68- DOTATATE;Ga-68-DOTATOC
44 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
45 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
46 An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma Recruiting NCT05023018 Phase 2 NEO100
47 A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma Recruiting NCT05425004 Phase 2 Cabozantinib
48 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib;Neratinib
49 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
50 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab

Search NIH Clinical Center for Lymphoplasmacyte-Rich Meningioma

Genetic Tests for Lymphoplasmacyte-Rich Meningioma

Anatomical Context for Lymphoplasmacyte-Rich Meningioma

Organs/tissues related to Lymphoplasmacyte-Rich Meningioma:

MalaCards : Brain, Spinal Cord, Pituitary, Bone

Publications for Lymphoplasmacyte-Rich Meningioma

Articles related to Lymphoplasmacyte-Rich Meningioma:

(show all 50)
# Title Authors PMID Year
1
A case of Lymphoplasmacyte-rich meningioma mimicking pachymeningitis. 62
35906535 2022
2
Extradural Spinal Lymphoplasmacyte-Rich Meningioma in the Thoracic Spine: A Case Report and Literature Review. 62
36238911 2022
3
Lymphoplasmacyte-rich meningioma: A rare histologic variant of benign meningioma with atypical bone invasion. 62
35079313 2022
4
Lymphoplasmacyte-rich meningioma with hematologic signs and PD-L1 over-expression. 62
35996712 2022
5
Lymphoplasmacyte-rich meningioma in the central nervous system: An unusual case report. 62
34967348 2021
6
A rare case of dumbbell-shaped lymphoplasmacyte-rich meningioma arising at the upper cervical spinal cord. 62
34030941 2021
7
Case Report: Creeping Growth in Lymphoplasmacyte-Rich Meningioma-A Radiologic Variant. 62
34970592 2021
8
Lymphoplasmacyte-rich meningioma with atypical cystic-solid feature: A case report. 62
33024789 2020
9
A rare cystic lymphoplasmacyte-rich meningioma: A case report and review of the literature. 62
33282453 2020
10
Large dural-based mass with bony hyperostosis in a 16-year-old male: IgG4-related disease mimicking lymphoplasmacyte-rich meningioma. 62
31073682 2019
11
Reader response: Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. 62
30833478 2019
12
Author response: Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. 62
30833479 2019
13
Lymphoplasmacyte-rich meningioma involving the whole intracranial dura mater. 62
29759995 2018
14
Lymphoplasmacyte-Rich Meningioma With Atypical Angiomatous Feature and an Increased Deposition of IgG4-Positive Plasma Cells: An Unusual Case Report. 62
28862040 2018
15
Primary Intraosseous Lymphoplasmacyte-Rich Meningioma. 62
28962957 2018
16
Clinical, Radiologic, and Pathologic Features of 56 Cases of Intracranial Lymphoplasmacyte-Rich Meningioma. 62
28673887 2017
17
Lymphoplasmacyte-rich meningioma with invasion of bone: A case report and review of literature. 62
27695559 2016
18
[Lymphoplasmacyte-rich meningioma: report of a case]. 62
27430701 2016
19
Report of a rare case of atypical lymphoplasmacyte-rich meningioma in the tentorium mimicking idiopathic hypertrophic pachymeningitis. 62
26902101 2016
20
Unusual clear cell, lymphoplasmacyte-rich, dural-based tumor with divergent differentiation: a tricky case mimicking a meningioma. 62
25912756 2015
21
Imaging findings and clinical features of intracal lymphoplasmacyte-rich meningioma. 62
25643346 2015
22
Isolated spinal Rosai-Dorfman disease misdiagnosed as lymphoplasmacyte-rich meningioma by intraoperative histological examination. 62
24577670 2015
23
IgG4 overexpression is rare in meningiomas with a prominent inflammatory component: a review of 16 cases. 62
24467316 2014
24
Meningeal Rosai-Dorfman disease mimicking meningioma. 62
24366336 2014
25
Intraventricular lymphoplasmacyte-rich meningioma: a case report. 62
25448216 2014
26
Gamma knife radiosurgery for lymphoplasmacyte-rich meningioma. 62
22964347 2013
27
Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. 62
23320997 2013
28
Sphenoid wing lymphoplasmacyte-rich meningioma with occasional emperipolesis closely simulating an intracranial Rosai-Dorfman disease: a diagnostic dilemma. 62
23211432 2013
29
Lymphoplasmacyte-rich meningioma: our experience with 19 cases and a systematic literature review. 62
23936588 2013
30
Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. 62
23104516 2013
31
An analysis of the magnetic resonance imaging and pathology of intracal lymphoplasmacyte-rich meningioma. 62
21354736 2012
32
Lymphoplasmacyte-rich meningioma: a convexity mass with regional enhancement in the adjacent brain parenchyma. 62
21732989 2012
33
A case of lymphoplasmacyte-rich meningioma of the jugular foramen. 62
21725644 2011
34
Lymphoplasmacyte-rich meningioma at the foramen magnum. 62
18661316 2008
35
Intracranial inflammatory pseudotumor: report of a rare case. 62
18282168 2008
36
A 72-year-old woman with right frontal extra-axial mass. 62
18363938 2008
37
Co-existing fibrous dysplasia and atypical lymphoplasmacyte-rich meningioma. 62
17645241 2007
38
Lymphoplasmacyte-rich meningioma mimicking idiopathic hypertrophic pachymeningitis. 62
17548990 2007
39
Idiopathic hypertrophic pachymeningitis mimicking lymphoplasmacyte-rich meningioma. 62
17548991 2007
40
Lymphoplasmacyte-rich meningioma with atypical invasive nature. 62
17245013 2007
41
Sphenoid ridge lymphoplasmacyte-rich meningioma. 62
16877241 2006
42
Lymphoplasmacyte rich meningioma. A case report and review of the literature. 62
15557881 2004
43
Intramedullary plasma cell granuloma in the cervicothoracic spine. Case report. 62
12296686 2002
44
October 2000: a 47 year old man with long-standing progressive tetraparesis. 62
11303801 2001
45
[Lymphoplasmacyte-rich meningioma: a report of three cases and a review of the literature]. 62
10347856 1999
46
Lymphoplasmacyte-rich meningioma with clinical resemblance to inflammatory pseudotumor. Report of two cases. 62
9126910 1997
47
Cystic lymphoplasmacyte-rich meningioma--case report. 62
9095629 1997
48
Lymphoplasmacyte-rich meningioma: a case report with histological and immunohistochemical studies. 62
9384804 1997
49
Meningeal sinus histiocytosis mimicking lymphoplasmacyte-rich meningioma. Case report. 62
8847571 1996
50
Lymphoplasmacyte-rich meningioma in a child. Case report. 62
7490624 1995

Variations for Lymphoplasmacyte-Rich Meningioma

Expression for Lymphoplasmacyte-Rich Meningioma

Search GEO for disease gene expression data for Lymphoplasmacyte-Rich Meningioma.

Pathways for Lymphoplasmacyte-Rich Meningioma

Pathways related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.69 SDC1 CD68

GO Terms for Lymphoplasmacyte-Rich Meningioma

Biological processes related to Lymphoplasmacyte-Rich Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron differentiation GO:0045665 8.92 OLIG2 MIB1

Sources for Lymphoplasmacyte-Rich Meningioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....